Form 4: Moderna Director Noubar Afeyan Sells Shares Worth Millions
SEC Form 4 Filing
Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on June 18, 2024, under a pre-arranged trading plan.
Summary
- On June 18, 2024, Noubar Afeyan, a director of Moderna, sold shares of the company's common stock.
- The sales were executed under a Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
- A total of 15,000 shares were sold in multiple transactions at varying prices.
- The prices ranged from $131.71 to $136.92 per share.
- After the reported transactions, Afeyan directly owns 2,299,015 shares of Moderna common stock.
- Afeyan also has indirect ownership through Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting insider trading activity. The sentiment is neutral as it simply reports facts without expressing any opinion or forward-looking statements.
Industry Context
Insider sales are a common occurrence in publicly traded companies. It is important to note that the sales were executed under a pre-arranged trading plan, which is a common practice to avoid accusations of insider trading. The market will likely interpret the sales in the context of Moderna's overall performance and future prospects.
Comparison to Industry Standards
- Comparing Moderna's insider trading activity to other biotechnology companies like Pfizer, BioNTech, and Johnson & Johnson can provide context.
- Analyzing the frequency and size of insider transactions relative to the company's market capitalization and trading volume is important.
- Rule 10b5-1 plans are a common tool used by executives at companies like Apple, Microsoft, and Amazon to manage their stock sales in a compliant manner.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a pre-arranged trading plan mitigates this concern.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2023-02-27 | Rule 10b5-1 trading plan adopted |
| 2023-11-07 | Rule 10b5-1 trading plan amended |
| 2024-06-18 | Date of stock sale transactions |
| 2024-06-21 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.